Health Care [ 10/12 ] | Pharmaceuticals [ 66/74 ]
NASDAQ | Common Stock
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States.
Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder.
The company is headquartered in Coral Gables, Florida.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 7, 24 | -0.59 Increased by +29.76% | -0.83 Increased by +28.92% |
| May 8, 24 | -0.72 Increased by +17.24% | -0.85 Increased by +15.29% |
| Mar 19, 24 | -0.84 Increased by +40.43% | -0.83 Decreased by -1.20% |
| Nov 8, 23 | -0.73 Increased by +44.27% | -0.91 Increased by +19.78% |
| Aug 8, 23 | -0.84 Increased by +36.84% | -0.90 Increased by +6.67% |
| May 11, 23 | -0.87 Increased by +37.86% | -0.89 Increased by +2.25% |
| Mar 23, 23 | -1.41 Increased by +21.67% | -1.33 Decreased by -6.02% |
| Nov 10, 22 | -1.31 Increased by +46.31% | -1.45 Increased by +9.66% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | N/A Decreased by N/A% | -21.73 M Increased by +1.25% | - - |
| Jun 30, 24 | 0.00 Decreased by N/A% | -17.77 M Increased by +29.78% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -21.83 M Increased by +17.07% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 0.00 Decreased by N/A% | -25.17 M Increased by +33.68% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -22.00 M Increased by +44.18% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -25.30 M Increased by +36.64% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -26.32 M Increased by +33.78% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -37.94 M Decreased by -10.37% | Decreased by N/A% Decreased by N/A% |